» Articles » PMID: 29947233

MicroRNAs in Pathophysiology of Acute Myocardial Infarction and Cardiogenic Shock

Overview
Specialty General Medicine
Date 2018 Jun 28
PMID 29947233
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Levels of circulating miRNA are considered to be potential biomarkers of acute myocardial infarction and disease progression.

Methods: In this study, the expression levels of circulating miRNA-1, miRNA-133 and miRNA-124a were investigated in a group of patients with acute myocardial infarction (STEMI) and cardiogenic shock (CS) compared to controls.

Results: During the hospitalization period, miRNA-133 showed a significant up-regulation in the serum of STEMI and CS patients compared to controls, while the expression of miRNA-1 was significantly different only in CS. The expression of miRNA-124 was significantly higher in STEMI and CS. Furthermore, miRNA-1 expression was related to the level of circulating glucose in patients with STEMI. We also found a negative correlation between miRNA-133 and MMP-9 levels. MiRNA-124 expression was significantly related to the level of soluble ST2; the marker correlated to cardiac damage.

Conclusion: All selected miRNAs are potential markers of cardiac injury in cardiogenic shock, whereas miRNA-124a and -133 are markers of injury in STEMI. MiRNA-1 expression is related to circulating glucose in STEMI. None of miRNAs could be correlated to the extent of injury, progress of the disease, or prognosis of patient outcome. Therefore, the levels of circulating miRNA have no potential for becoming a biomarker of myocardial damage and as such would bring no further benefit compared to current markers (Tab. 4, Fig. 1, Ref. 47).

Citing Articles

Emerging Gene Therapy Based on Nanocarriers: A Promising Therapeutic Alternative for Cardiovascular Diseases and a Novel Strategy in Valvular Heart Disease.

Yang H, Li J, Song C, Li H, Luo Q, Chen M Int J Mol Sci. 2025; 26(4).

PMID: 40004206 PMC: 11855571. DOI: 10.3390/ijms26041743.


Prioritization of microRNA biomarkers for a prospective evaluation in a cohort of myocardial infarction patients based on their mechanistic role using public datasets.

Venugopal P, George M, Damal Kandadai S, Balakrishnan K, Uppugunduri C Front Cardiovasc Med. 2022; 9:981335.

PMID: 36407428 PMC: 9668885. DOI: 10.3389/fcvm.2022.981335.


Activation of PTEN/P13K/AKT Signaling Pathway by miRNA-124-3p-Loaded Nanoparticles to Regulate Oxidative Stress Attenuates Cardiomyocyte Regulation and Myocardial Injury.

Cheng Y, He Q, Li N, Luo M Oxid Med Cell Longev. 2022; 2022:8428596.

PMID: 36267811 PMC: 9578799. DOI: 10.1155/2022/8428596.


Marathon-Induced Cardiac Strain as Model for the Evaluation of Diagnostic microRNAs for Acute Myocardial Infarction.

Shirvani Samani O, Scherr J, Kayvanpour E, Haas J, Lehmann D, Gi W J Clin Med. 2022; 11(1).

PMID: 35011745 PMC: 8745173. DOI: 10.3390/jcm11010005.


Current Knowledge of MicroRNAs (miRNAs) in Acute Coronary Syndrome (ACS): ST-Elevation Myocardial Infarction (STEMI).

Tanase D, Gosav E, Ouatu A, Badescu M, Dima N, Ganceanu-Rusu A Life (Basel). 2021; 11(10).

PMID: 34685428 PMC: 8541211. DOI: 10.3390/life11101057.